Comirnaty®

BIOLOGICAL6 trials

Conditions

COVID-19Covid19Covid19 VaccineEvaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy VolunteersSARS CoV-2SARS-CoV-2 InfectionSARS-CoV2

Phase 1

Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.

NCT05490108

Shanghai Zerun Biotechnology Co.,LtdCOVID-19, SARS-CoV-2 Infection

Start: 2022-06-02End: 2023-08-31Updated: 2023-04-20

Phase 2

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

Active, not recruitingNCT06672055

VaxartCOVID-19, SARS-CoV2

Start: 2024-10-08End: 2027-05-01Target: 5485Updated: 2026-06-25

A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults

CompletedNCT06742281

CyanVac LLCCOVID-19

Start: 2024-12-05End: 2026-06-15Updated: 2026-07-10

mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes

Not yet recruitingNCT06919796

PharmaJet, Inc.Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2

Start: 2025-05-01End: 2026-11-25Target: 40Updated: 2025-04-15

Phase 3

IntraDermal Versus Intramuscular Comirnaty® Efficacy Study

WithdrawnNCT05029245

Department of Medical Services Ministry of Public Health of ThailandCovid19, Covid19 Vaccine

Start: 2021-08-31End: 2022-10-31Updated: 2022-05-11

Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older

WithdrawnNCT05534048

Everest Medicines (Singapore) Pte. Ltd.SARS-CoV-2 Infection

Start: 2023-02-03End: 2023-12-20Updated: 2026-09-11

Related Papers

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.